Generic Name and Formulations:
Iron (as sodium ferric gluconate complex in sucrose) 12.5mg/mL; soln for IV inj or infusion; contains benzyl alcohol.
Indications for NULECIT:
Iron deficiency anemia in patients on chronic hemodialysis receiving epoetin therapy.
Give by IV infusion (diluted) or slow IV inj (undiluted). 125mg infused over 1 hour or by slow IV inj (at a rate of up to 12.5mg/min). Minimum cumulative dose: 1g given over 8 sequential dialysis sessions; usual max: 125mg/dose.
<6yrs: not recommended. Give by IV infusion (diluted) over 1 hour. ≥6yrs: 1.5mg/kg per dose at 8 sequential dialysis sessions; max: 125mg/dose.
Anemias not caused by iron deficiency. Iron overload.
Hemoglobinopathies. Refractory anemias. Avoid in neonates. Pregnancy (Cat. B). Nursing mothers.
May reduce absorption of concomitant oral iron preparations.
Hypotension, hypertension, GI upset, chest pain, back pain, abdominal pain, pruritus, inj site reaction, cramps, headache, dizziness, syncope, fatigue, fever, dyspnea, tachycardia; rare: hypersensitivity reactions.
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma
- Patient Fears of Placebo Use in Clinical Trials
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|